BlackRock’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-3,560,931
| Closed | -$146M | – | 5317 |
|
|
2024
Q2 | $146M | Sell |
3,560,931
-1,887,689
| -35% | -$77.2M | ﹤0.01% | 1794 |
|
|
2024
Q1 | $230M | Sell |
5,448,620
-578,905
| -10% | -$24.5M | 0.01% | 1547 |
|
|
2023
Q4 | $256M | Buy |
6,027,525
+1,036,499
| +21% | +$43.9M | 0.01% | 1474 |
|
|
2023
Q3 | $109M | Buy |
4,991,026
+158,319
| +3% | +$3.46M | ﹤0.01% | 1920 |
|
|
2023
Q2 | $154M | Buy |
4,832,707
+347,766
| +8% | +$11.1M | ﹤0.01% | 1762 |
|
|
2023
Q1 | $109M | Buy |
4,484,941
+2,678
| +0.1% | +$65.3K | ﹤0.01% | 1938 |
|
|
2022
Q4 | $141M | Buy |
4,482,263
+293,892
| +7% | +$9.27M | ﹤0.01% | 1760 |
|
|
2022
Q3 | $118M | Buy |
4,188,371
+56,084
| +1% | +$1.58M | ﹤0.01% | 1842 |
|
|
2022
Q2 | $109M | Buy |
4,132,287
+740,872
| +22% | +$19.6M | ﹤0.01% | 1928 |
|
|
2022
Q1 | $119M | Sell |
3,391,415
-93,242
| -3% | -$3.26M | ﹤0.01% | 2008 |
|
|
2021
Q4 | $113M | Buy |
3,484,657
+121,379
| +4% | +$3.94M | ﹤0.01% | 2123 |
|
|
2021
Q3 | $99.2M | Buy |
3,363,278
+710,720
| +27% | +$21M | ﹤0.01% | 2195 |
|
|
2021
Q2 | $68M | Buy |
2,652,558
+1,554,987
| +142% | +$39.8M | ﹤0.01% | 2463 |
|
|
2021
Q1 | $15.1M | Buy |
1,097,571
+2,180
| +0.2% | +$29.9K | ﹤0.01% | 3284 |
|
|
2020
Q4 | $18.2M | Buy |
+1,095,391
| New | +$18.2M | ﹤0.01% | 2991 |
|